ID   RT112 CP1.5
AC   CVCL_C7JU
SY   CP1.5
DR   Wikidata; Q117704825
RX   PubMed=10422815;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1670 ! RT-112
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 21-03-23; Last updated: 29-06-23; Version: 2
//
RX   PubMed=10422815; DOI=10.1007/s002400050103;
RA   Siegsmund M.J., Marx C., Seemann O., Schummer B., Steidler A.,
RA   Toktomambetova L., Kohrmann K.-U., Rassweiler J., Alken P.;
RT   "Cisplatin-resistant bladder carcinoma cells: enhanced expression of
RT   metallothioneins.";
RL   Urol. Res. 27:157-163(1999).
//